Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Net Cash Flow (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Net Cash Flow for 13 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 13.12% to -$1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.4 million, a 153.55% decrease, with the full-year FY2025 number at -$5.4 million, down 153.55% from a year prior.
  • Net Cash Flow was -$1.5 million for Q4 2025 at Ekso Bionics Holdings, up from -$2.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $36.7 million in Q1 2021 to a low of -$8.7 million in Q4 2022.
  • A 5-year average of -$582150.0 and a median of -$2.8 million in 2022 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 1688.58% in 2021; the steepest drop was 294.27% in 2021.
  • Ekso Bionics Holdings' Net Cash Flow stood at -$3.1 million in 2021, then plummeted by 182.3% to -$8.7 million in 2022, then soared by 85.26% to -$1.3 million in 2023, then tumbled by 38.23% to -$1.8 million in 2024, then rose by 13.12% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Net Cash Flow are -$1.5 million (Q4 2025), -$2.5 million (Q3 2025), and -$2.9 million (Q2 2025).